These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 25037477)
1. [Adiponectin as target in rheumatoid arthritis]. Neumann E; Frommer KW; Müller-Ladner U Z Rheumatol; 2014 Aug; 73(6):556-8. PubMed ID: 25037477 [No Abstract] [Full Text] [Related]
2. One year in review: novelties in the treatment of rheumatoid arthritis. Guidelli GM; Barskova T; Brizi MG; Lepri G; Parma A; Talarico R; Cantarini L; Frediani B Clin Exp Rheumatol; 2015; 33(1):102-8. PubMed ID: 25719499 [TBL] [Abstract][Full Text] [Related]
3. [Adipocytokines as driving forces in rheumatoid arthritis]. Neumann E; Knedla A; Meier F; Tarner IH; Büchler C; Schäffler A; Müller-Ladner U Z Rheumatol; 2007 Mar; 66(2):139-41. PubMed ID: 17333076 [No Abstract] [Full Text] [Related]
4. [TNF-inhibitors slow down joint destruction in rheumatoid arthritis. No cure, but dramatic relief of symptoms]. Wollheim FA Lakartidningen; 2001 May; 98(21):2560-2. PubMed ID: 11433990 [No Abstract] [Full Text] [Related]
5. Th17 Cells in Immunopathogenesis and treatment of rheumatoid arthritis. Azizi G; Jadidi-Niaragh F; Mirshafiey A Int J Rheum Dis; 2013 Jun; 16(3):243-53. PubMed ID: 23981743 [TBL] [Abstract][Full Text] [Related]
6. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. Boissier MC; Semerano L; Challal S; Saidenberg-Kermanac'h N; Falgarone G J Autoimmun; 2012 Sep; 39(3):222-8. PubMed ID: 22704962 [TBL] [Abstract][Full Text] [Related]
7. The immunomodulatory role of PDEs inhibitors in immune cells: therapeutic implication in rheumatoid arthritis. He Y; Huang Y; Mai C; Pan H; Luo HB; Liu L; Xie Y Pharmacol Res; 2020 Nov; 161():105134. PubMed ID: 32798648 [TBL] [Abstract][Full Text] [Related]
8. Targeted drug development for arthritis. Malemud CJ Future Med Chem; 2012 Apr; 4(6):701-3. PubMed ID: 22530633 [No Abstract] [Full Text] [Related]
9. IL-17 as a future therapeutic target for rheumatoid arthritis. van den Berg WB; Miossec P Nat Rev Rheumatol; 2009 Oct; 5(10):549-53. PubMed ID: 19798029 [TBL] [Abstract][Full Text] [Related]
10. Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples. Combe B; van Vollenhoven R Ann Rheum Dis; 2013 Sep; 72(9):1433-5. PubMed ID: 23625979 [No Abstract] [Full Text] [Related]
11. IL-17, now an important target for treatment in arthritis! Miossec P Joint Bone Spine; 2017 May; 84(3):247-249. PubMed ID: 28017822 [No Abstract] [Full Text] [Related]
12. Rheumatoid arthritis: inflammation and bone loss. Schett G Wien Med Wochenschr; 2006 Jan; 156(1-2):34-41. PubMed ID: 16465612 [TBL] [Abstract][Full Text] [Related]
18. Predictive value of ultrasonographic assessment of disease activity in response to tumor necrosis factor-α inhibitor treatment in rheumatoid arthritis: a prospective cohort study. Inanc N; Ozen G; Direskeneli H Clin Exp Rheumatol; 2016; 34(1):156. PubMed ID: 26575409 [No Abstract] [Full Text] [Related]
19. Current insights and future prospects for the pathogenesis and treatment for rheumatoid arthritis. Koga T; Kawakami A; Tsokos GC Clin Immunol; 2021 Apr; 225():108680. PubMed ID: 33493672 [TBL] [Abstract][Full Text] [Related]